Sex Enhancement Flibanserin Women Pharmaceutical Intermediates for Sexual Desire Disorder

Female Sex Enhancement  Flibanserin for Sexual Desire Disorder 

 

Flibanserin, sold under the trade name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three. 

 

The certainty of the estimate is low. The side effects of dizziness, sleepiness, and nauseaoccur about three to four times more often.Development by Boehringer Ingelheim was halted in October 2010 following a negative evaluation by the U.S. 

 

HSDD was recognized as a distinct sexual function disorder for more than 30 years, but was removed from theDiagnostic and Statistical Manual of Mental Disorders in 2013, and replaced with a new diagnosis calledfemale sexual interest/arousal disorder (FSIAD).

 

Mechanism of action

 

Flibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors.

 

It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to reduction in serotonin levels and increase in dopamine and norepinephrine levels, all of which may play part in reward processing.

 

Female Sex Enhancement  Flibanserin for Sexual Desire Disorder 

 

Flibanserin, sold under the trade name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication increases the number of satisfying sexual events per month by about one half over placebo from a starting point of about two to three. 

 

The certainty of the estimate is low. The side effects of dizziness, sleepiness, and nauseaoccur about three to four times more often.Development by Boehringer Ingelheim was halted in October 2010 following a negative evaluation by the U.S. 

 

HSDD was recognized as a distinct sexual function disorder for more than 30 years, but was removed from theDiagnostic and Statistical Manual of Mental Disorders in 2013, and replaced with a new diagnosis calledfemale sexual interest/arousal disorder (FSIAD).

 

Mechanism of action

 

Flibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors.

 

It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to reduction in serotonin levels and increase in dopamine and norepinephrine levels, all of which may play part in reward processing.